Currently, in the USA, the founder of Medicinal Technologies scientist Dr. Sheryene Tejeda MD, Ph.D., MHS, MFS discovers an unprecedented cure for Endometriosis. Following years of research and clinical trials, this noteworthy doctor has made medical history with a revolutionary medical breakthrough. 

Valued at over $5 Billion dollars, the protocol is already being pursued purchase by several of the largest pharmaceutical companies worldwide. Endogen, not having yet been made available for purchase due to the influx of potential buyers and manufacturing policies, is a biomedical protocol for Endometriosis that’s said to have few to no side effects and does not require a prescription. It will initially be offered in the US but ultimately can be purchased worldwide. This protocol will change the lives of many globally as according to statistics over 250 million women are diagnosed with Endometriosis, and millions more remain undiagnosed.

 Until now there has been no viable remedy for the condition, causing women to seek relief through hormonal suppression, surgery and pain medications, all of which are temporary methods of addressing its symptoms. The 3-part protocol Endogen, however, was developed as a multi-faceted approach for reversing the root cause of the disease. Additionally, during further clinical trials, it has shown promising results for the dissemination of cysts, fibroids, and other relative conditions.

Endometriosis is characterized by the presence and growth of endometrial tissues outside of the uterine cavity. This disease that affects women of reproductive age involves a hormone-dependent inflammatory process that can occur during pre or post-ovulation and heightened during a woman’s menstrual cycle

. Women experience varying levels of pain which can at times be debilitating. Ultimately the disease often results in loss of fertility,  pelvic and other complications as the endometrial lesions spread to other organs. Endometriosis is progressive in nature and is staged by a medical professional. Though its source of development has until now been unclear, the past 30 years of diagnostic records shows a global prevalence estimate of 71%. Prevalence rates differ with respect to the symptoms and stages, but the disease overall is affected by the wellbeing of the woman.

Dr. Tejeda’s proposed mechanism of action for the development of Endometriosis has gained scientific and academic acclaim (?(?X GnRH ? JEG3f )+ (?? ^?ER ) ? NR3A1 ? 300-437pg/ml e (? +30dy)? ?EEC) and expresses how the developmental process of Endometriosis involves the primary deviation in the GnRH gene, which is responsible for the production of gonadotropin-releasing hormone, an important regulator of the female reproductive system. This scientific equation is anticipated to change the course of biomedical history as it offers a never before observed correspondence between a monogenetic gene mutation and the development of Endometriosis.

Prior to the research findings of Dr. Tejeda, it was unknown if Endometriosis was a condition, disorder, disease, or had genetic factors. 

Thanks to successfully conducting clinical trials and research, Dr. Tejeda asserts “we now know it is in fact a disease with epi genetic biomarkers”. Although new to the industry, Medicinal Technologies is a forerunner for innovative biomedicine and biotechnology, holding several patents for protocols and devices. Its founder Dr. Tejeda, not  limited to reproductive endocrinology related conditions, continues research on both common and rare diseases and disorders with the goal of offering answers and solutions.